WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their IKT stock forecasts and price targets.

Forecast return on equity

Is IKT forecast to generate an efficient return?

Company
-66.75%
Industry
121.15%
Market
270.27%
IKT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IKT forecast to generate an efficient return on assets?

Company
-60.14%
Industry
37.98%
IKT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IKT earnings per share forecast

What is IKT's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.52
Avg 2 year Forecast
-$0.73
Avg 3 year Forecast
-$0.72

IKT revenue forecast

What is IKT's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

IKT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IKT$1.54N/AN/A
HURA$2.29$12.00+424.02%Buy
OVID$1.63$1.50-7.98%Buy
WHWK$2.41N/AN/A
MGNX$1.84$3.50+90.22%Buy
View Top Biotech Stocks

Inhibikase Therapeutics Stock Forecast FAQ

What is IKT's earnings growth forecast for 2025-2027?

(NASDAQ: IKT) Inhibikase Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.65%.

Inhibikase Therapeutics's earnings in 2025 is -$41,504,901.On average, 4 Wall Street analysts forecast IKT's earnings for 2025 to be -$38,383,519, with the lowest IKT earnings forecast at -$37,973,677, and the highest IKT earnings forecast at -$39,121,233. On average, 4 Wall Street analysts forecast IKT's earnings for 2026 to be -$54,568,532, with the lowest IKT earnings forecast at -$61,342,094, and the highest IKT earnings forecast at -$47,727,905.

In 2027, IKT is forecast to generate -$53,435,879 in earnings, with the lowest earnings forecast at -$59,151,305 and the highest earnings forecast at -$47,727,905.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.

What is IKT's revenue growth forecast for 2025-2027?

(NASDAQ: IKT) Inhibikase Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 290%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.36%.

Inhibikase Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast IKT's revenue for 2025 to be $0, with the lowest IKT revenue forecast at $0, and the highest IKT revenue forecast at $0. On average, 4 Wall Street analysts forecast IKT's revenue for 2026 to be $0, with the lowest IKT revenue forecast at $0, and the highest IKT revenue forecast at $0.

In 2027, IKT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is IKT's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: IKT) forecast ROA is -60.14%, which is lower than the forecast US Biotechnology industry average of 37.98%.

What is IKT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IKT) Inhibikase Therapeutics's current Earnings Per Share (EPS) is -$0.04. On average, analysts forecast that IKT's EPS will be -$0.52 for 2025, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.53. On average, analysts forecast that IKT's EPS will be -$0.73 for 2026, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.64. In 2027, IKT's EPS is forecast to hit -$0.72 (min: -$0.79, max: -$0.64).

What is IKT's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: IKT) forecast ROE is -66.75%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.